Chronic pain treatment developer Medlab Clinical has received good results from its 12-month observation study of NanaBis, a cannabinoid treatment for cancer-induced bone pain which will help it progress towards a global Phase III study slated to commence in 2021.
NanaBis is a highly purified blend of THC:CBD that has been optimised for use at sub-micron (nano-sized) doses using Medlab’s proprietary drug delivery platform, NanoCelle. It is being developed as non-opioid alternative for the treatment of cancer-induced bone pain.
Join the Cannabiz revolution
Want to stay ahead of the cannabis curve with the latest local and
international news, analysis and intelligence and access to Australia's legal cannabis industry?
This article is included with our Premium subscription.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
